[1. Torbicki A, Perrier A, Konstantin ides S, Agnelli G, Galie N, Pruszczyk P, et al. Guidelines on the diagnosis and management of acute pulmonary embolism.The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Eu Heart J. 2008;29:2276-315.10.1093/eurheartj/ehn310]Search in Google Scholar
[2. Goldhaber SZ. Venous thromboembolism: epidemiology and magnitude of the problem. Best Pract Res Clin Haematol. 2012;25(3):235-42.10.1016/j.beha.2012.06.007]Search in Google Scholar
[3. Anderson FA Jr, Wheeler HB, Goldbeig RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med. 1991; 151:933-8.10.1001/archinte.1991.00400050081016]Search in Google Scholar
[4. Goldhaber SZ, Hennekens CH, Evans DA, Newton EC, Godleski JJ. Factors associated with correct antemortem diagnosis of major pulmonary embolism. Am J Med. 1982;73(6):822-6.10.1016/0002-9343(82)90764-1]Search in Google Scholar
[5. Rodger M, Wells PS. Diagnosis of pulmonary embolism. Thromb Res. 2001; 103(6): V225 -3 8.10.1016/S0049-3848(01)00326-7]Search in Google Scholar
[6. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registiy (ICOPER). Lancet. 1999;353:1386-9.10.1016/S0140-6736(98)07534-5]Search in Google Scholar
[7. Dulicuek P, Maly J, Pesuavova L, Pecka M. Prevalence of inherited thrombophilia in young thrombosis patients from the East Bohemian region. Blood Coagul Fibrinolysis. 2002; 13(6):569-73.10.1097/00001721-200209000-0001312192310]Search in Google Scholar
[8. British Thoracic Society Standards of Care Committee. Pulmonary Embolism Guideline Development Group. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax. 2003;5 8:470-84.10.1136/thorax.58.6.470174669212775856]Search in Google Scholar
[9. Rosendaal FR, KosterT, Vandenbrouck JP, Reitsma PH. High risk of thrombosis in patients homozygous for lactor V Leiden (activated protein C resistance). Blood. 1995;85:1504-8.10.1182/blood.V85.6.1504.bloodjournal8561504]Search in Google Scholar
[10. Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Factor V Leiden andtherisk for venous thromboembolism in the adult Danish population. Ann Intern Med. 2004; 140:330-7.10.7326/0003-4819-140-5-200403020-0000814996674]Search in Google Scholar
[11. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q.JBiolChem. 1995;270:4053-7.]Search in Google Scholar
[12. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica. 2002;87:1095-108.]Search in Google Scholar
[13. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;8 8( 10):3698-703.10.1182/blood.V88.10.3698.bloodjournal88103698]Search in Google Scholar
[14. Bezemer ID, Doggen CJ, Vos HL, Rosendaal FR. No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study. Arch Intern Med. 2007; 167(5) :497-501.10.1001/archinte.167.5.497]Search in Google Scholar
[15. Castro R, Rivera I, Blom H. J, Jakobs C, De Almeida I. T. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview. J Inherit MetabDis. 2006;29(l):3-20.10.1007/s10545-006-0106-5]Search in Google Scholar
[16. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. JAMA. 2004 ;291:565-75.10.1001/jama.291.5.565]Search in Google Scholar
[17. Fermo I, D'Angelo SV, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early onset venous and arterial occlusive disease. Ann Intern Med. 1995;123:747-53.10.7326/0003-4819-123-10-199511150-00002]Search in Google Scholar
[18. De Bree A, Verschuren WM, Bjorke-Monsen AL, Van der Put NM, Heil SG, Trijbels FJ, et al. Effect of the methylenetetrahydrofolate reductase 677C-->T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample. Am JClinNutr. 2003;77:687-93.10.1093/ajcn/77.3.687]Search in Google Scholar
[19. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. P1A1/A2 polymorphism of platelet glycoprotein Ilia and risk of myocardial infarction, stroke and venous thrombosis. Lancet. 1997;349:385-58.10.1016/S0140-6736(97)80010-4]Search in Google Scholar
[20. Renner W, Winkler M, Hoffinann C, Koppel H, Seinost G, Brodmann M, et al. The P1A1/A2 polymorphism of platelet glycoprotein Ilia is not associated with deep venous thrombosis. Int Angiol. 2001 ;20(2): 148-51.]Search in Google Scholar
[21. Francis C. Plasminogen activator inhibitor-1 levels and polymorphisms. Association with venous thromboembolism. Arch Pathol Lab Med. 2002; 126(11): 1401-4.10.5858/2002-126-1401-PAILAP12421149]Search in Google Scholar
[22. Tsantes AE,Nikolopoulos GK, BagosPG,RaptiE, Mantzios G, Kapsimali V, et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis. Thromb Haemost 2007;97(6):907-13.10.1160/TH06-12-0745]Search in Google Scholar
[23. Komsa-Penkova R,Kovacheva- Kotseva K, Angelova S, SavovA, Scmionova M. Selected methods of DN A analysis and clinical applications. Pleven: MU-Pleven; 2004.]Search in Google Scholar
[24. Ivanov P, Komsa-Penkova R, Ivanov Y, Ivanov I, Matkov O, Beshev L [4G/5G polymorphism in the gene for plasminogen activator inhibitor-1 in patients it may be a deep vein thrombosis]. Modcma Medicina. 2009;60(l-2):35-9. [in Bulgarian].]Search in Google Scholar
[25. Kwok S, Higuchi R. Avoiding false-positives with PCR. Nature. 1989;339:237-8.10.1038/339237a02716852]Search in Google Scholar
[26. Ivanov P, Komsa-Penkova R, Kovacheva K, Ivanov Y, Stoyanova A, Ivanov I, Pavlov P, Glogovska P, Nojarov V. Impact of genetic factors on pulmonary embolism - early onset and recurrent incidences. Lung. 2008;186(1)^7-36.10.1007/s00408-007-9061-718097719]Search in Google Scholar
[27. Ridker PM, Miletich JP, Stampfcr MJ, Goldhabcr SZ, Lindpaintncr K, Hennekeas CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800-2.10.1161/01.CIR.92.10.2800]Search in Google Scholar
[28. Perry SL, Ortel TL. Clinical and laboratory evaluation of thrombophilia Clin Chest Med 2003;24:153-70.]Search in Google Scholar
[29. Nizankowska-Mogilnicka E, Adamek L, Grzanka P, Domagala T.B, Sanak M , Krzanowski M, Szczcklik A. Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis. EurRespir J. 2003 ;21(1 ):25-30.10.1183/09031936.03.0003430212570104]Search in Google Scholar
[30. Ogzulgcn IK, Eim NN , Akar N, Dcmircl K, Ki-tapei M. The role of thrombophilic risk factors in the severity of pulmonary embolism. Eur Respir J. 2002; 19(4):705-11.]Search in Google Scholar
[31. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166(7):729-36.10.1001/archinte.166.7.72916606808]Search in Google Scholar
[32. Roscndaal FR, Doggen CJ,ZivelinA, Arruda VR, Aiach M, Siscovick DS, ct al. Geographic distribution of the 20210 G to A prothrombin variant. Thro mb Haemost. 1998;79(4):706-70.10.1055/s-0037-1615049]Search in Google Scholar
[33. De Stefano V, Martinclli I, Mannucci PM, Pacia-roni K, Rossi E, Chiusolo P, et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol. 2001; 113(3 ):630-5.10.1046/j.1365-2141.2001.02827.x11380448]Search in Google Scholar
[34. Kwak SH, Wang XQ, He Q, Fang WF, Mitra S, Bdcir K, et al. Plasminogen activator inhibitor-1 potentiates LPS-inducod neutrophil activation through a JNK-mediated pathway. Thromb Haemost. 2006;95(5):829-35.10.1160/TH05-12-0782]Search in Google Scholar
[35. Pcdroja BS, Kang LE, Imas AO, Carmeliet P, Bernstein AM. Plasminogen activator inhibitor-1 regulates integrin alpha v bcta3 expression and autocrine transforming growth factor beta signaling. J Biol Chem. 2009 ^ 84(31):20708-17.10.1074/jbc.M109.018804274283619487690]Search in Google Scholar
[36. Abboud N, Ghazouani L, Saidi S, Ben-Hadj-Kha-lifa S, Addad F, Almawi WY, ctal. Association of PAI-1 4G/5G and - 844G/Agcne poly-morphlsms and changes in PAI -1 /tissue plasminogen activator levels in myocardial infarction: a case-control study. Genet Test Mol Biomarkers. 2010;14( 1):23-7.10.1089/gtmb.2009.003919929406]Search in Google Scholar
[37. Saidi S, Slamia LB, Mahjoub T, Ammou SB, Almawi WY. Association of PAI-1 4G/5G and -844G/A gene polymorphism and changes in PAI-1A PA levels in stroke: a case-control study. Stroke Ccrebrovasc Dis. 2007;16(4): 153-9.10.1016/j.jstrokecerebrovasdis.2007.02.00217689411]Search in Google Scholar
[38. Tsantes AE, Nikolopoulos GK, Bagos PG, Bono-vas S, Koptcridcs P, Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res. 2008;122(6):736-42.10.1016/j.thromres.2007.09.005]Search in Google Scholar
[39. Eichingcr S, Pabingcr I, Stiimpflcn A, Hirschl M, Bialonczyk C, Schneider B, et al. The risk of recurrent venous thromboembolism in patients with and without factorV Leiden. Thromb Haemost. 1997;77:624-8.10.1055/s-0038-1656023]Search in Google Scholar
[40. Lindmarkcr P, Schulman S, Sten-Linder M, Wiman B, Egbcrg N, Johnsson H., et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost. 1999;81:684-9.10.1055/s-0037-1614554]Search in Google Scholar
[41. Simioni P, Prandoni P, Lensing AW, Scudcllcr A, Sardclla C, Prias MH, et al. The risk of recurrent venous thromboembolism in patients with an Arg506->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997;336:399-403.10.1056/NEJM199702063360602]Search in Google Scholar
[42. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet 1992;340:873-6.10.1016/0140-6736(92)93285-U]Search in Google Scholar
[43. Prandoni P, Leasing AW, Cogo A, Cuppini S, Villalta S, Carta M,Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinicalcourse of acute deep venous thrombosis. AnnlntcrnMod. 1996;125:1-7.]Search in Google Scholar
[44. Geno J. Merli. Pathophysiology of venous thrombosis, thrombophilia, and the diagnosis of deep vein thrombosis-pulmonarycmbolism in the elderly. Clin Geriatr Med. 2006;22:75-92. 10.1016/j.cger.2005.09.01216377468]Search in Google Scholar